|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In the clinical samples of HNSCC, high expression of TrkA and panTrk were more associated with oropharyngeal and p16 positive squamous cell carcinoma (SCC).
|
30360033 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Perineural invasion (p = 0.009), p16 status (p = 0.009), non-oropharyngeal primary site (p = 0.002), and the use of chemotherapy (p = 0.01) were independent predictors of positive PET/CT.
|
30680587 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Research underway is currently delineating the role of HPV and p16 testing in non-oropharyngeal sites.
|
30575409 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Sixteen patients (eight oral cavity, eight oropharyngeal) completed rapamycin and definitive treatment.Half of patients were p16 positive.
|
30420444 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to evaluate the 8th edition of the American Joint Committee on Cancer Staging Manual: Head and Neck Section on oropharyngeal squamous cell cancer (OPSCC) and to clarify the relationship between p16 overexpression and the presence of human papillomavirus (HPV) DNA using fresh frozen samples.
|
30594962 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
TNM8 staging for oropharyngeal squamous cell carcinomas (OPSCC) surrogates p16 immunohistochemistry for HPV testing.
|
30890775 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Under a shared use agreement, 547 patients from Radiation Therapy Oncology Group 0129 and 0522 with nonmetastatic oropharyngeal squamous cell cancers who had a known p16 status and smoking status were analyzed to assess the association of clinical features with the development of distant metastases.
|
30548235 |
2019 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Clear Cell Carcinoma of Salivary Glands Is Frequently p16 Positive: A Pitfall in the Interpretation of Oropharyngeal Biopsies.
|
29076874 |
2018 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We retrospectively included 50 histologically confirmed p16 positive oropharyngeal squamous cell carcinomas (p16 positive immunostaining was defined by a strong staining in 70% or more of tumor cells).
|
29925856 |
2018 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV tumor status testing may be performed by surrogate marker p16 immunohistochemistry either on the primary tumor or from cervical nodal metastases only if an oropharyngeal primary tumor is present.
|
30188786 |
2018 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We used multivariable Cox regression to analyze the effect of p16 status on overall survival (OS), cancer-specific survival (CSS), and competing mortality (CM) for oropharyngeal or nonoropharyngeal tumor sites.All statistical tests were two-sided.
|
29878161 |
2018 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Results The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70% nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV.
|
29251996 |
2018 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
RPPA data suggest high p16 protein expression in many HPV (-) non-oropharyngeal HNSCCs, limiting its potential utility as an HPV biomarker outside of the oropharynx.
|
30098776 |
2018 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
High-risk human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas have a more favorable prognosis than HPV-negative ones. p16 immunohistochemistry has been recommended as a prognostic test in clinical practice.
|
28621317 |
2017 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Fifty-nine oropharyngeal specimens from 2 university hospitals in Japan were examined for morphology and p16 immunohistochemistry.
|
27913709 |
2017 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Human papillomavirus (HPV) association of oropharyngeal SCC was detected by p16 immunohistochemistry.
|
27385398 |
2017 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The HPV status of 515 patients with oropharyngeal SCC diagnosed between 1987 and 2010 was determined by HPV E6-targeted multiplex real time polymerase chain reaction assay (PCR) and p16 immunohistochemistry.
|
25521312 |
2016 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Greater study is needed to explain the high p16 negativity among this HPV-positive oropharyngeal SCC African American cohort.
|
25962720 |
2016 |
|
Oropharyngeal disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased p16 expression is also seen in squamous neoplasms arising at other sites, including head, neck, and oropharyngeal tract.
|
26400483 |
2015 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
All of the positive controls, but none of the oropharyngeal samples stained positively for p16.
|
26590333 |
2015 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry for p16 protein is often used as a surrogate marker for oncogenic HPV in the oropharyngeal tissues, although alternative HPV DNA testing methods are under intensive study.
|
26650695 |
2015 |
|
Oropharyngeal disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer.
|
26183400 |
2015 |
|
Oropharyngeal disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-34a tumor levels significantly correlated with oropharyngeal origin (p=0.0284) and p16 positivity (p=0.0218).
|
25862914 |
2015 |
|
Oropharyngeal disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of p16 was predominantly found in oropharyngeal squamous cell cancer patients (OPSCC; 36.6% positivity; 92% of all cases), while EGFR was expressed at high levels in all tumor subsites (82%). p16 expression was associated with improved overall survival in irradiated OPSCC patients (2-year overall survival of 80% in p16-positive vs. 33% overall survival in p16-negative patients).
|
24715244 |
2014 |
|
Oropharyngeal disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The purpose of this study is to investigate the prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas.
|
24470584 |
2014 |